COVID-19 in DMARD-treated patients with inflammatory rheumatic diseases: Insights from an analysis of the World Health Organization pharmacovigilance database.

Amandine DernoncourtJean SchmidtPierre DuhautSophie LiabeufValérie Gras-ChampelKamel MasmoudiYoussef BennisBenjamin Batteux

Published in: Fundamental & clinical pharmacology (2021)

Our results are in line with the literature on a potentially better safety profile for anti-IL-6 agents and JAK inhibitors. The WHO pharmacovigilance data suggest that COVID-19 is significantly more frequent in patients with IRDs treated with TNF inhibitors.

Keyphrases

coronavirus disease
adverse drug
sars cov
electronic health record
systematic review
drug induced
rheumatoid arthritis
oxidative stress
emergency department
big data
newly diagnosed
machine learning
data analysis